Shots:

• The P-III (KEYNOTE-394) trial evaluates Keytruda (IV, q3w, for 35 cycles) +BSC vs PBO + BSC in 453 patients in Asia with advanced HCC prior treated with sorafenib or oxaliplatin-based CT
• The results showed an improvement in 1EPs of OS; 21% reduction in risk of death; m-OS (14.6mos. vs 13.0mos.); patients were alive @2yrs. (34.3% vs 24.9%) while an efficacy EPs showed a 26% reduction in risk of disease progression or death; m-PFS (2.6mos. vs 2.3mos.); ORR (12.7% vs 1.3%); m-DOR (23.9mos. vs 5.6mos.)
• The therapy is being evaluated in multiple studies as monothx. & combination with other treatments. The company has a global development program of 7 trials & expects to enroll ~3,000 patients

Ref: Businesswire | Image: Merck